Genomic Prediction
PrivateLast Round
Series A
Extension
Dec 15, 2021
Total Funding Raised
$16.5M
Company Overview
Genomic Prediction operates in Healthcare & Life Sciences and is based in New Jersey. Its latest recorded funding round was a Series A Extension round in December 2021.
Genomic Prediction is a biotechnology company that provides advanced genomic tests which improve in-vitro fertilization (IVF) health outcomes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Healthcare Analytics, Medical AI
Business Model
B2B2C
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genomic Prediction Comparables
Compare Genomic Prediction with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Orchid | 93% | |
| Reprocare Genetics | 87% | |
| Juno Genetics | 86% |
For institutional investors. Book with your work email.
Genomic Prediction Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Dec 15, 2021 | ||||
| Series A | Jan 31, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Genomic Prediction Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NimbleVentures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 19, 2026
Santiago Munné appointed as Chief Scientific Officer.
- Oct 23, 2025
Accused of trade secret misappropriation by Nucleus Genomics.
For institutional investors. Book with your work email.
Genomic Prediction Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Genomic Prediction's valuation, stock price, and market status.
Is Genomic Prediction a public or private company?
Genomic Prediction is a private company.
What is the current stock price of Genomic Prediction?
Genomic Prediction is a private company, so its shares have no public market price. Caplight tracks Genomic Prediction's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Genomic Prediction worth (valuation)?
Valuation information for Genomic Prediction is not publicly available.
Can I buy Genomic Prediction stock?
Genomic Prediction shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Genomic Prediction's last funding round?
Genomic Prediction's most recent funding round was Series A Extension on December 15, 2021.
Who are the main investors in Genomic Prediction?
Key investors in Genomic Prediction include NimbleVentures.
Will Genomic Prediction IPO soon?
No public IPO plans have been announced for Genomic Prediction.
How can I track Genomic Prediction secondary market activity?
Caplight tracks bids, offers, and trades in Genomic Prediction's shares on secondary markets.